Top Markets
Coin of the day
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Peringkat dalam Saham #170
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily... Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Harga Saham
$519.38
Terakhir disinkronkan: 2026-09-14
Kapitalisasi Pasar
$131.82B
Perubahan (1 hari)
0.76%
Perubahan (1 tahun)
32.09%
Negara
US
Perdagangan Vertex Pharmaceuticals Incorporated (VRTX)

Kategori

Pendapatan untuk Vertex Pharmaceuticals Incorporated (VRTX)
Pendapatan pada Jun 2026 TTM: $12.62B
Menurut laporan keuangan terbaru dari Vertex Pharmaceuticals Incorporated, pendapatan saat ini (TTM) adalah $12.62B. Pada tahun 2024, perusahaan menghasilkan pendapatan sebesar $11.02B peningkatan dibandingkan pendapatan pada tahun 2023 yang sebesar $9.87B. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Vertex Pharmaceuticals Incorporated dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $12.62B 5.19%
2025 $12.00B 8.90%
2024 $11.02B 11.66%
2023 $9.87B 10.51%
2022 $8.93B 17.91%
2021 $7.57B 22.06%
2020 $6.21B 49.07%
2019 $4.16B 36.59%
2018 $3.05B 22.46%
2017 $2.49B 46.20%
2016 $1.70B 64.89%
2015 $1.03B 77.86%
2014 $580.42M -52.11%
2013 $1.21B -20.63%
2012 $1.53B 8.25%
2011 $1.41B 883.91%
2010 $143.37M 40.49%
2009 $102.05M -41.85%
2008 $175.50M -11.81%
2007 $199.01M -8.02%
2006 $216.36M 34.47%
2005 $160.89M 56.63%
2004 $102.72M 48.56%
2003 $69.14M -57.08%
2002 $161.09M -3.82%
2001 $167.49M 114.38%
2000 $78.13M 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
$6.02B -52.30%
NL
$15.74B 24.71%
AU
$2.23B -82.35%
US
- -
CH
$10.11B -19.91%
BE